DCGI Drug Advertising Rules prohibit direct-to-consumer advertising of prescription drugs in India — only OTC with valid registration is permitted.
DCGI Drug Advertising Rules cover the Drugs Controller General of India's regulatory framework on how prescription drugs may (and may not) be advertised to the public in India. Prescription drugs cannot be advertised direct-to-consumer; only OTC formulations with a valid registration can, and even then within Magic Remedies Act constraints.
How it works.
- Classify the product accurately. Schedule H, H1, X, OTC — each has different advertising rules.
- For OTC: verify registration validity. Advertising an expired-registration product is a separate compliance offence.
- Draft ad content against Magic Remedies Act list. The 54 diseases the Act prohibits treatment-claim ads for.
- Add cautionary language required by rule. Where mandated — dosage warnings, contraindications, "consult a doctor" footers.
- Route through legal + regulatory sign-off. Every ad, every variant.
- Store approval trail for 5+ years. DCGI investigation windows can extend back several years.
Why it matters for
Indian healthcare.
DCGI Drug Advertising Rules are the strictest advertising regime in Indian healthcare marketing. The combination of DCGI, Magic Remedies (Objectionable Advertisement) Act 1954, Drugs and Cosmetics Act 1940, and ASCI healthcare guidelines produces a very narrow window where consumer-facing pharma marketing is permitted. Prescription drugs are essentially outside that window entirely for DTC. OTC products sit inside a heavily-constrained window that prohibits claims for 54 named diseases. Enforcement in 2024-2026 has stepped up sharply, with DCGI-driven takedowns of Meta and Google ads, and consumer-court orders against platforms hosting non-compliant creatives. The ICG pharma content practice treats every consumer-facing pharma creative as a documented legal deliverable, not a marketing deliverable.
How ICG uses this.
ICG maintains a rolling DCGI-compliance library for managed pharma clients — 54-disease list, prohibited claim patterns, cautionary-language templates. Every creative routes through both marketing and legal-regulatory sign-off before live deployment. Related: Magic Remedies Act, Schedule H, Schedule H1, ASCI Medical Guidelines.
Frequently asked questions.
Can a pharma company advertise a Schedule H drug?
Not direct-to-consumer. Ethical advertising to doctors via medical journals, MR calls, and closed-CME channels is permitted. Any public-facing ad promoting a Schedule H drug is a DCGI breach and typically also a Magic Remedies Act breach.
What about "consult your doctor" ads?
Awareness ads that name a condition (not a drug) and direct patients to a doctor are permitted. Once the ad names the drug or implies a specific molecule, it crosses into prohibited DTC territory.
Can Meta and Google host these ads?
Both platforms enforce DCGI-aligned pharma policies. Meta requires pharma advertisers to be pre-authorised and restricts targeting. Google prohibits prescription-drug ads to Indian audiences unless under a narrow ethical-advertising exception.
Does DCGI cover medical devices?
Partially — devices classified under the Medical Devices Rules 2017 have distinct advertising rules that overlap with DCGI in some categories (in-vitro diagnostics, drug-eluting stents) and diverge in others.
Audit your pharma ads
against DCGI rules.
ICG runs a free 30-min Brand & Growth Diagnostic that plugs into your live account and surfaces this metric against portfolio benchmarks.
